Chengdu Kanghong Pharmaceutical (SHE:002773) was named a proposed winner in China's 12th batch of national centralized drug volume-based procurement for perampanel tablets.
The drug treats partial-onset and primary generalized tonic-clonic seizures in adults and children, according to a Monday filing with the Shenzhen bourse.
Under the program, procurement runs through December 2029.
Shares of the pharmaceutical company were up 1% in recent trade.